MARGetuximab Or Trastuzumab (MARGOT)
A phase 2 trial of Paclitaxel / nab-paclitaxel, Pertuzumab, Margetuximab, Trastuzumab and Trastuzumab biosimilars in Breast cancer and HER2-positive breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.
Overview
MARGetuximab Or Trastuzumab (MARGOT) is a phase 2 interventional study registered as NCT04425018 by Dana-Farber Cancer Institute, with 174 participants planned, started 2020-07-13 and due to reach its primary completion in 2024-10-24. Interventions recorded: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab. Conditions recorded: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer.
Linked to the drug Margetuximab because the registry names it among its interventions and Breast cancer and HER2-positive breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Shares Trastuzumab biosimilars, Breast cancer (all types), Trastuzumab, Paclitaxel / nab-paclitaxel and the tag pipeline.
- TrialMargetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Shares Margetuximab, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Shares Trastuzumab biosimilars, Pertuzumab, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialOptimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Shares Pertuzumab, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialRadiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialCombination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Shares Margetuximab, Trastuzumab and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.